https://www.marketscreener.com/quote/stock/ULTRAGENYX-PHARMACEUTICAL-15672076/news/Ultragenyx-GeneTx-FDA-Removes-Hold-Study-of-GTX-102-in-Angelman-Syndrome-36526135/?utm_source=telegram&utm_medium=social&utm_campaign=share